Please assess the completion status of the following clinical trial:

Trial Title: Study of Oral Treatments for Hepatitis C

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* HCV Genotype 1a or 1b~* Adult patients (age 18 years or older)~* Patients being prescribed HCV treatment who can begin treatment with any of the three HCV treatments being studied (Harvoni (SOF/LDV), Viekira Pak (PrOD) (Phase 1 only), or Zepatier (EBR/GZR))~Exclusion Criteria:~* Inability to provide written informed consent~* HARVONI® is not a covered drug on benefits formulary~* Current or historical evidence of hepatic decompensation (variceal bleeding, hepatic encephalopathy, or ascites)~* Child Pugh (CTP) B or C Cirrhosis (documented CTP calculation is required)~* Pregnant or breastfeeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EBR/GZR (elbasvir/grazoprevir) with RBV (Type: ACTIVE_COMPARATOR): Patients received 1 EBR/GZR (elbasvir/grazoprevir) (Zepatier) tablet (50/100mg) once daily for 12 to 16 weeks (provider discretion) with Ribavirin (RBV) 200 mg/tablet, 1-3/day, taken 1-2 times per day (dosage at discretion of provider).
- EBR/GZR (elbasvir/grazoprevir) (Type: ACTIVE_COMPARATOR): Patients received 1 EBR/GZR (elbasvir/grazoprevir) tablet (50/100 mg) once daily for 12 to 16 weeks (provider discretion) (without Ribavirin)
- SOF/LDV (sofosbuvir/ledipasvir) with RBV (Type: ACTIVE_COMPARATOR): Patients received 1 SOF/LDV (sofosbuvir/ledipasvir) (Harvoni) tablet (400/90 mg) orally once daily with or without food 12 to 24 weeks with ribavirin (RBV) (at discretion of provider). RBV taken as 200 mg/tablet(capsule), 1-3 pills/day, 1-2 times/day.
- SOF/LDV (sofosbuvir/ledipasvir) (Type: ACTIVE_COMPARATOR): Patients received 1 SOF/LDV (sofosbuvir/ledipasvir) tablet (400/90 mg) orally once daily with or without food 12 to 24 weeks without ribavirin (RBV) (per discretion of provider)
- PrOD (Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir) with RBV (Phase 1 only) (Type: ACTIVE_COMPARATOR): Patients received Pr0D (Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir) orally daily with food for 12 to 24 weeks with RBV (Ribavirin). Ombitasvir/Paritaprevir/Ritonavir (12.5/75/50 mg/tablet) -2 tablets once daily with food for 12 to 24 weeks and 1 dasabuvir tablet (250 mg) twice daily with food for 12 to 24 weeks.~RBV (200 mg/pill) 1-3 pills/day, 1-2 times/day (use and dosage at provider discretion). Total daily RBV dosage ranged from 200 to 1200 mg.
- PrOD (ombitasvir/paritaprevir/ritonavir and dasabuvir) (Type: ACTIVE_COMPARATOR): Patients received 2 ombitasvir/paritaprevir/ritonavir tablets (12.5/75/50 mg) once daily and 1 dasabuvir (250 mg) tablet twice daily with food for 12 to 24 weeks without Ribavirin (as per provider instructions)

Based on this trial design, predict the completion outcome and termination type (if applicable).